| Literature DB >> 33644648 |
Christoph Bauer1, Désirée Furthner2, Eva Grohmann1, Gerald Tulzer1.
Abstract
BACKGROUND: Vitamin K deficiency bleeding is a life-threatening complication in early infancy. Exclusive breastfeeding and neonatal cholestasis syndromes, most notable α-1-antitrypsin deficiency, have been reported to be risk factors. Intracranial haemorrhage is most common. No association to haemopericardium has been reported before. CASEEntities:
Keywords: Alpha-1-antitrypsin deficiency; Cardiac tamponade; Case report; Haemopericardium; Infant; Vitamin K deficiency bleeding
Year: 2020 PMID: 33644648 PMCID: PMC7898583 DOI: 10.1093/ehjcr/ytaa481
Source DB: PubMed Journal: Eur Heart J Case Rep ISSN: 2514-2119
| Age: | Events: |
|---|---|
| Past medical history: healthy at term-born girl, breast and partially formula fed, received 2 mg of vitamin K p.o. after birth, during the 1st week and after 7 weeks. | |
| 10 + 4 weeks | Weakness, vomiting, sucking weakness |
| 10 + 6 weeks | Admission to local hospital due to aggravating symptoms |
| 11 + 0 weeks |
Sudden drop in haemoglobin level (6.3 g/dL, normal 9.2–15.0 g/dL), administration of erythrocytes, new onset of pericardial effusion Transfer to our intensive care unit, signs of cardiogenic shock, emergency pericardiocentesis (drainage of 150 ml blood), milrinone i.v., replacement of deranged coagulation parameters, administration of 1 mg vitamin K i.v. Diagnosis of cholestatic liver disease, reduced α-1-antitrypsin level (37 mg/dL, normal 90–120 mg/dL), white matter lesion (cerebral-magnetic resonance imaging) |
| 11 + 2 weeks |
removal of pericardial tubes, exclusion of biliary atresia (liver biopsy), exclusion of viral hepatitis (serology) initiation of vitamin deficiency replacement therapy: cholecalciferol, tocopherol, retinol and vitamin K |
| 12 + 3 weeks |
Genetic testing: homozygotic mutation of the SERPINA1-gene (c.1096G>A), PiZZ-type confirmed α-1-antitrypsin deficiency Discharge: without any neurologic deficits |
| 35 + 4 weeks | Latest outpatient visit: appropriate weight gain, no developmental delay or neurologic deficits, continuation of the vitamin deficiency replacement therapy |